Amgen drug cuts prostate cancer bone problems
A third pivotal trial of Amgen Inc’s denosumab found that it significantly delayed the likelihood of suffering fractures and other bone complications in men with advanced prostate cancer compared with current therapy.

Read more on Reuters via Yahoo! News